Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating safety, tolerability, and pharmacokinetics of SBC-102 (Sebelipase alfa) in adults with lysosomal acid lipase deficiency, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholesterol Ester Storage Disease
• Lysosomal Acid Lipase Deficiency

Drugs mentioned

• SBC-102 (Sebelipase alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-12-11